Switch to
More onapp

Vivimed Labs Ltd

VIVIMEDLAB
MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹75 cr, stock is ranked 2,383
High RiskStock is 3.09x as volatile as Nifty
8.950.20 (-2.19%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
MaterialsSpecialty Chemicals
SmallcapWith a market cap of ₹75 cr, stock is ranked 2,383
High RiskStock is 3.09x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-1.12
PB RatioPB Ratio
0.09
Dividend YieldDiv. Yield
Sector PESector PE
13.63
Sector PBSector PB
2.65
Sector Div YldSctr Div Yld
2.30%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Vivimed Labs Limited is an India-based company, which is primarily engaged in the business of active pharmaceuticals ingredients, contract development and manufacturing operations (CDMO) finished dosage formulation, specialty chemicals and retail branded formulation manufacturing. It operates in two segments: Specialty Chemicals Business and Pharma Business. It serves various companies through the contract manufacturing (CMO) division, which offers a range of products, such as capsules and tablets, syrups and liquids, and nasal sprays and ointments. The active ingredients manufactured by the Company are used in home and personal care segments, such as hair, skin, oral care and anti-microbial preservatives. Its products include DICLOFENAC GEL BP, LULICONAZOLE CREAM, PERMETHRIN LOTION, and CLOTRIMAZOLE VAGINAL GEL. Its subsidiaries include Finoso Pharma Private Limited, Vivimed Specialty Chemicals Private Limited, Vivimed Holdings Limited, and Vivimed Labs USA INC.

Financial TrendFinancial statements 

20192020202120221.341.070.870.240.06-0.11-0.08-0.07
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.02%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 22, 2022

Vivimed Labs Limited has informed the Exchange about related party transaction for the period ended April 2022 | Download

Vivimed Labs Limited has informed the Exchange about related party transaction for the period ended April 2022 | Download

Outcome of Board Meeting 
Announced OnNov 14, 2022

Vivimed Labs Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022 | Download

Vivimed Labs Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022 | Download

Cash Dividend 
Ex. DateSep 19, 2018

Final • Div/Share: ₹ 0.4

See all events